Elicio Therapeutics Director Venkatesan Jay Receives 21,750-Share Award

What Happened
Venkatesan Jay, a member of Elicio Therapeutics' (ELTX) board, was granted a derivative equity award covering 21,750 shares on 2026-08-31. The grant is reported as $0.00 on the Form 4 because it is an equity award (stock option/award), not a cash purchase or sale. No immediate cash changed hands and the filing does not state a strike price or fair-market value.

Key Details

• Transaction date: 2026-08-31; Form 4 filed: 2026-09-02 (appears timely).
• Transaction type: Award/Grant (derivative). Reported amount: 21,750 shares; reported price: $0.00.
• Vesting/exercise: Per footnote, the option award vests and becomes exercisable in full on the earlier of (A) August 31, 2027 (one-year anniversary) or (B) the 2027 annual meeting, subject to continued service.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Other notes: Filing includes Exhibit 24.1 (Power of Attorney). Footnote states no additional equity award will be made to the director in connection with the 2026 annual meeting.

Context

• This is a standard non-employee director equity award (common routine compensation for board members). It is a derivative grant that will only convert into exercisable options/shares if vesting conditions are met; it does not indicate an immediate buy or sell.
• Because no exercise or sale occurred, there is no immediate cash impact or change in open-market holdings reported in this transaction.